Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02886715 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
A Phase 3 study, sponsored by Fougera Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,110
- Enrollment target
NCT02886715: Completed Phase 3 study, sponsored by Fougera Pharmaceuticals.
NCT02886715 is a Phase 3 study that has completed, run by Fougera Pharmaceuticals. The registered enrollment target is 1,110 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02886715, a Phase 3 study, has completed, sponsored by Fougera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,110 participants
- Enrollment target
Study Summary
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris
Primary Outcome
Percent change from baseline to week 12 in the inflammatory (papules and pustules) lesion counts
Interventions
- DRUG Placebo
- DRUG Tazarotene Cream 0.1%
- DRUG Tazorac®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,110 participants |
| Start Date | 2016-09-21 |
| Est. Completion | 2017-05-31 |
| Phase | Phase 3 |
What the finished NCT02886715 record still lists
NCT02886715 is an interventional study that assigns participants to a tested intervention. Its 1,110 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02886715 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02886715 about?
NCT02886715 is a clinical study titled "A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris". A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris
What is the current status of trial NCT02886715?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,110 participants. The study started on 2016-09-21. Estimated completion is 2017-05-31.
What interventions are being tested in trial NCT02886715?
The interventions under investigation include: Placebo (DRUG), Tazarotene Cream 0.1% (DRUG), Tazorac® (DRUG).
Who is sponsoring clinical trial NCT02886715?
This trial is sponsored by Fougera Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02886715's enrollment target sits among peer trials
1,110 251st of 2000 higher than 1,750 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02140255 · 1,120 participants · Phase 1
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
- NCT06618534 · 1,120 participants · Phase 2
Azithromycin for Meningococcal Carriage
- NCT07164131 · 1,120 participants · Phase 4
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI